In two phase 3 clinical trials involving more than 1,200 premenopausal women, PT-141 (bremelanotide) was shown to significantly improve sexual desire and reduce distress related to low desire compared with placebo ( Kingsberg et al., 2019, Obstetrics & Gynecology )
(2020, Drug Testing and Analysis) developed an immunopurification + high-resolution mass spectrometry method to detect Long R3-IGF-I and Des(1-3)-IGF-I in athlete samples establishing that IGF-1 LR3 is detectable by current anti-doping methods
Additionally, GLP-1 suppresses the release of glucagon, a hormone that raises blood glucose levels, further contributing to glycaemic control
*Correspondence: Rosa Maria Bruno [email protected] This article was submitted to Autonomic Neuroscience, a section of the journal Frontiers in Physiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
As with any newer-entry health technology, accessibility is largely relegated to people with good commercial insurance and high socio-economic brackets. The impact will only increase By 2030, as these drugs become more widely used, its predicted that more than 9% of the U.S
